Table 2 Outcome parameters pre- and post- propensity score matching*.
unmatched cohort (total n = 1041) | matched cohort (total n = 328) | |||||||
|---|---|---|---|---|---|---|---|---|
control group (total n = 868) | treatment group (total n = 173) | p value | ATT (95% confidence intervall) | control group (total n = 164) | treatment group (total n = 164) | p value | ATT (95% confidence intervall) | |
(Ln)NT-proBNP [ng/l] | 7.1 ± 1.7 (n = 168) | 6.9 ± 1.6 (n = 41) | 0.588 | −0.2 (−0.7 to 0.4) | 7.5 ± 1.9 (n = 34) | 6.8 ± 1.6 (n = 39) | 0.087 | −0.7 (−1.5 to 0.1) |
Ejection fraction [%] | 47.8 ± 14.7 (n = 354) | 46.2 ± 13.4 (n = 70) | 0.400 | −1.6 (−5.3 to 2.2) | 46.8 ± 16.5 (n = 68) | 45.6 ± 13.4 (n = 66) | 0.641 | −1.2 (−6.4 to 3.9) |
IVS [mm] | 12.9 ± 2.3 (n = 464) | 12.6 ± 2.2 (n = 122) | 0.385 | −0.2 (−0.7 to 0.2) | 13.3 ± 2.4 (n = 93) | 12.6 ± 2.1 (n = 114) | 0.029 | −0.7 (−1.3 to −0.1) |
LVEDD [mm] | 53.6 ± 8.5 (n = 540) | 54.4 ± 8.1 (n = 141) | 0.164 | 0.8 (−0.8 to 2.4) | 52.6 ± 9.0 (n = 109) | 54.6 ± 8.0 (132) | 0.131 | 2.1 (−0.7 to 4.2) |
LA-PLAX [mm] | 45.2 ± 7.4 (n = 168) | 44.9 ± 7.8 (n = 140) | 0.463 | −0.2 (−1.6 to 1.2) | 45.0 ± 7.6 (n = 96) | 44.8 ± 7.8 (n = 131) | 0.554 | −0.2 (−2.2 to 1.8) |
QRS duration [ms] | 120.0 ± 69.6 (n = 391) | 123.1 ± 31.7 (n = 145) | 0.010 | 3.0 (−8.7 to 14.8) | 117.4 ± 27.7 (n = 72) | 123.5 ± 31.9 (n = 137) | 0.137 | 6.2 (−2.6 to 14.9) |
QT duration [ms] | 411.8 ± 49.7 (n = 244) | 413.8 ± 58.8 (n = 135) | 0.794 | 1.9 (−9.3 to 13.1) | 420.5 ± 40.8 (n = 45) | 417.2 ± 52.2 (n = 127) | 0.396 | −3.3 (−20.2 to 13.7) |
QTc duration [ms] | 448.7 ± 190.6 (n = 251) | 443.9 ± 54.8 (n = 140) | 0.249 | −4.8 (−37.2 to 27.6) | 445.2 ± 45.3 (n = 47) | 446.5 ± 48.6 (n = 132) | 0.858 | 1.4 (−14.6 to 17.4) |
